Save Big On Every Program at Cyber Trading University Through the End of 2023.

Cyber Trading University


 LianBio Nasdaq:($LIAN) has been making headlines in the stock market as its stock price has surged by an astounding 165.5% in just one week, as confirmed by data from S&P Global Market Intelligence. This dramatic rise serves as a clear signal to day traders that an exceptional opportunity awaits.

The Driving Forces Behind $lian's SURGE:

On October 24, 2023, $LIAN made a groundbreaking announcement, unveiling an exclusive agreement with Bristol Myers Squibb.

This agreement gave $LIAN the exclusive rights to develop and commercialize its Mavacamten heart medication in various regions, including mainland China, Hong Kong, Macau, Taiwan, Singapore, and Thailand.

Adding to the excitement, the very next day, $LIAN shared favorable clinical trial data for its Infigratinib drug. These clinical trials were aimed at treating locally advanced or metastatic gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ) and were showcased at the European Society for Medical Oncology (ESMO) Congress.


THE Financial Windfall:

 Thanks to its pivotal agreement with Bristol Myers Squibb, $LIAN is set to receive a substantial one-time cash payment of $350 million. In addition, the company is now free from prior payment obligations, which could have amounted to as much as $127.5 million under the previous licensing agreement for Mavacamten with MyoKardia.

Bristol Myers Squibb also plans to extend employment offers to some of $LIAN's existing staff.

THE path forward for LIANBIo:

The collaboration with Bristol Myers and the significant financial boost has positioned LianBio on a solid footing financially. To put it in perspective, $LIAN's current market capitalization hovers around the $404 million mark.

Beyond the Mavacamten agreement, $LIAN has unveiled promising results for its Infigratinib drug. The clinical data underscores its efficacy in treating gastric cancers, with no adverse events leading to dose discontinuation, mortality, or drug-induced liver injury. Notably, Chinese regulators have granted it the esteemed "breakthrough therapy" designation for the treatment of gastric cancer, potentially paving the path for even greater gains.

Final Thoughts

As a day trader, staying well-informed, adeptly managing risk, and astutely seizing the right opportunities are the foundations of success in this high-risk, high-reward arena. 

Here's to successful trading.

See you tomorrow in my CyberGroup Live Trading room (Open Monday thru Friday from 7:45am - 4:30pm EST)

If you aren't already a member, you can sign up today at

Happy Trading,

Fausto Pugliese
Founder & CEO
Cyber Trading University

Share this article:



More Posts